SG Americas Securities
MRNS

SG Americas Securities’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

SG Americas Securities’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,178
Closed -$34K – 3661
2024
Q2 		$34K Buy
+29,178
New +$73K ﹤0.01% 2732
2024
Q1 		– Sell
-12,289
Closed -$134K – 3567
2023
Q4 		$134K Buy
+12,289
New +$92.1K ﹤0.01% 2514
2022
Q1 		– Sell
-59,972
Closed -$712K – 3564
2021
Q4 		$712K Sell
59,972
-10,861
-15% -$125K ﹤0.01% 1892
2021
Q3 		$806K Buy
+70,833
New +$974K ﹤0.01% 2089
2021
Q2 		– Sell
-18,142
Closed -$281K – 3325
2021
Q1 		$281K Buy
+18,142
New +$262K ﹤0.01% 2435
2020
Q3 		– Sell
-11,504
Closed -$117K – 3603
2020
Q2 		$117K Buy
11,504
+4,388
+62% +$40.4K ﹤0.01% 3274
2020
Q1 		$58K Buy
+7,116
New +$61.6K ﹤0.01% 3154

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SG Americas Securities's MRNS Position: Q3 2024 in Review

SG Americas Securities sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 29,178 shares — an estimated $34K sold.

SG Americas Securities first reported a position in MRNS in Q1 2020 and held it in 7 quarters. The position peaked at $806K in Q3 2021. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • SG Americas Securities reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • SG Americas Securities sold 29,178 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $34K.
  • SG Americas Securities first reported a position in Marinus Pharmaceuticals, Inc in Q1 2020 and held it in 7 quarters.
  • SG Americas Securities's Marinus Pharmaceuticals, Inc position peaked at $806K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on SG Americas Securities's 13F filing for Q3 2024, filed 3 Oct 2024.